Valuation: Sernova

Market Cap 4.15Cr 2.95Cr 2.59Cr 2.41Cr 2.21Cr 284.06Cr 4.22Cr 29Cr 11Cr 139.65Cr 11Cr 11Cr 482.86Cr P/E 2026 *
-3.67x
P/E 2027 * -2.75x
Enterprise Value 4.15Cr 2.95Cr 2.59Cr 2.41Cr 2.21Cr 284.06Cr 4.22Cr 29Cr 11Cr 139.65Cr 11Cr 11Cr 482.86Cr EV / Sales 2026 *
-
EV / Sales 2027 * 8.31x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 week-4.35%
Current month-18.52%
1 month-21.43%
3 months-36.23%
6 months-35.29%
Current year-15.38%
1 week 0.11
Extreme 0.11
0.12
1 month 0.1
Extreme 0.105
0.14
3 years 0.1
Extreme 0.105
0.96
5 years 0.1
Extreme 0.105
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 55 -
Chairman 75 23/09/2025
Director/Board Member 60 19/04/2012
Change 5-day change 1-year change 3-year change Capi.($)
-8.33%-4.35%-43.59%-88.42% 2.95Cr
+3.54%+3.25%-18.16%+13.52% 13TCr
+1.92%-0.96%-2.85%-4.52% 1.28TCr
+0.95%-2.07%+62.86%+106.79% 901.61Cr
-6.12%-1.94%-48.53%-70.40% 438.94Cr
-0.21%-2.71%-1.65%+36.76% 262.55Cr
-2.59%-0.76%-20.35%-25.38% 158.84Cr
-3.05%-2.46%-27.45%-34.57% 157.87Cr
+3.72%-0.15%-1.85%-57.71% 155.59Cr
Average -0.23%-1.82%-11.29%-13.77% 2TCr
Weighted average by Cap. +2.81%+2.14%-12.90%+13.84%

Financials

2026 *2027 *
Net sales - 50L 35.5L 31.18L 29L 26.61L 34Cr 50.77L 3.44Cr 1.35Cr 17Cr 1.33Cr 1.3Cr 58Cr
Net income -1.28Cr -91.08L -80L -74.4L -68.27L -88Cr -1.3Cr -8.83Cr -3.45Cr -43Cr -3.42Cr -3.35Cr -149.1Cr -1.98Cr -1.4Cr -1.23Cr -1.15Cr -1.05Cr -135.2Cr -2.01Cr -14Cr -5.32Cr -66Cr -5.27Cr -5.16Cr -229.82Cr
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
24/26/24 CA$0.1100 -8.33%
23/26/23 CA$0.1200 0.00%
22/26/22 CA$0.1200 +9.09%
21/26/21 CA$0.1100 0.00%
20/26/20 CA$0.1100 -4.35%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100CAD
Average target price
0.4500CAD
Spread / Average Target
+309.09%

Quarterly revenue - Rate of surprise